Patents by Inventor Michael Schlabach
Michael Schlabach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787813Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.Type: GrantFiled: October 11, 2022Date of Patent: October 17, 2023Assignee: KSQ Therapeutics, Inc.Inventors: Jehrod Burnett Brenneman, Elsa Beyer Krall, Michael Schlabach, Andrew Alistair Wylie
-
Publication number: 20230203046Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: October 11, 2022Publication date: June 29, 2023Inventors: Jehrod Burnett BRENNEMAN, Elsa Beyer KRALL, Michael SCHLABACH, Andrew Alistair WYLIE
-
Patent number: 11485736Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.Type: GrantFiled: December 19, 2019Date of Patent: November 1, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Jehrod Burnett Brenneman, Elsa Beyer Krall, Michael Schlabach, Andrew Alistair Wylie
-
Publication number: 20220228155Abstract: The present disclosure provides super-repressors capable of inhibiting the transcription of NR4A1, NR4A2, and NR4A3 target genes. The super-repressors can be used to enhance the effector functions of immune cells, e.g., for adoptive cell therapy. Methods of treating disorders using the modified immune cells are also provided.Type: ApplicationFiled: May 21, 2020Publication date: July 21, 2022Inventors: Michael SCHLABACH, Brian Alexander SOSA-ALVARADO
-
Patent number: 11332713Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: November 18, 2020Date of Patent: May 17, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Patent number: 11261428Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: March 14, 2019Date of Patent: March 1, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Patent number: 11111493Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: February 14, 2020Date of Patent: September 7, 2021Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo
-
Publication number: 20210115049Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5?, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: December 19, 2019Publication date: April 22, 2021Inventors: Jehrod Burnett BRENNEMAN, Elsa Beyer KRALL, Michael SCHLABACH, Andrew Alistair WYLIE
-
Publication number: 20210071140Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: November 18, 2020Publication date: March 11, 2021Inventors: Micah BENSON, Jason MERKIN, Gregory V. KRYUKOV, Solomon Martin SHENKER, Michael SCHLABACH, Noah TUBO, James Martin KABERNA, II
-
Publication number: 20200347386Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: February 4, 2020Publication date: November 5, 2020Inventors: Micah BENSON, Michael SCHLABACH, Gregory KRYUKOV, Anne Louise CADZOW, Isabelle Fleur LE MERCIER, Frank STEGMEIER
-
Publication number: 20200181610Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Micah BENSON, Jason MERKIN, Gregory V. KRYUKOV, Solomon Martin SHENKER, Michael SCHLABACH, Noah TUBO
-
Publication number: 20190284553Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 14, 2019Publication date: September 19, 2019Inventors: Micah BENSON, Jason MERKIN, Gregory V. KRYUKOV, Solomon Martin SHENKER, Michael SCHLABACH, Noah TUBO
-
Publication number: 20190284530Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 14, 2019Publication date: September 19, 2019Inventors: Micah BENSON, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Publication number: 20190284529Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 14, 2019Publication date: September 19, 2019Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo
-
Publication number: 20180153919Abstract: The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.Type: ApplicationFiled: September 7, 2016Publication date: June 7, 2018Inventors: Brian Bettencourt, Stuart Milstein, Ivanka Toudjarska, Earl McDonald, Michael Schlabach, JR., Frank P. Stegmeier, Markus Warmuth, Kalyani Gampa, Dieter Huesken, Mark Stump, Jan Weiler, Zainab Jagani
-
Publication number: 20150238515Abstract: The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.Type: ApplicationFiled: April 30, 2013Publication date: August 27, 2015Inventors: Brian Bettencourt, Stuart Milstein, Ivanka Jarska, Earl McDonald, Michael Schlabach, JR., Frank P. Stegmeier, Markus Warmuth, Kalyani Gampa, Dieter Huesken, Mark Stump, Jan Weiler, Zainab Jagani
-
Publication number: 20110081362Abstract: Described herein are methods based, in part, on the discovery of genes or gene products that can be down-modulated to inhibit the growth and survival of a cell, such as a cancer cell. In one embodiment, the genes or gene targets are preferentially expressed in a cell having an activating Ras mutation (e.g., a cancer cell), which permits selective inhibition of growth in cells bearing an activating Ras mutation without affecting cells lacking enhanced Ras activity. In addition, the methods described herein provide for determining cancer prognosis in an individual bearing an activating Ras mutation.Type: ApplicationFiled: February 2, 2009Publication date: April 7, 2011Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Stephen J. Elledge, Ji Luo, Michael Schlabach, Nicole Solimini